Flamma

Overview

Flamma is a privately held, family-run CDMO with over 70 years of experience (founded 1950) specializing in small molecule Active Pharmaceutical Ingredients (APIs), New Chemical Entities (NCEs), Registered Starting Materials (RSMs), and Key Intermediates. The company operates a global supply chain with FDA-inspected cGMP facilities in Italy, a GMP site in the USA, and a 100% owned and operated GMP facility in China.

Core Capabilities

• Custom Manufacturing — full-scale production from early-stage to commercial delivery
• Custom Development — process optimization and scale-up support
• cGMP Manufacturing — compliant production across multiple geographies

Specialized Technologies

• Highly Potent API (HPAPI) — dedicated manufacturing for potent compounds
• Continuous Flow Chemistry — advanced flow-based synthesis
• Cryogenic (Low Temperature) API Manufacturing — specialized low-temp processes
• Crystallization Research & Solid State Chemistry — polymorph screening and characterization
• Common Technologies — standard synthetic routes and scale-up

Recognition

Flamma has received multiple industry awards, including recognition as a Top 10 CMO in Europe by Pharma Tech Outlook. The company was the only small molecule CDMO rated as a TOP PERFORMER in all 6 CDMO Core Award Categories (Expertise, Reliability, Capabilities, Quality, Service, Compatibility) and all 7 Specialty Award Categories (Accessible Senior Management, State-of-the-Art, Innovation, On-Time Delivery, Right the First Time, Strength of Science, Reputation) in the CDMO Leadership Award evaluation of 110 CDMOs.

Facilities

Flamma operates multiple production and development sites across three continents, enabling flexible supply chain management and regulatory compliance across major markets.